ip articles

Patentability of Embryonic Stem Cells in Mexico

23 May 2018
Patentability of Embryonic Stem Cells in Mexico

By Moeller IP Advisors

Stem cells have the potential to treat a wide range of diseases and constitute a key research tool in the development of novel therapies and personalised medicine. There are two major types of stem cells: adult and embryonic. Embryonic stem (ES) cells seem to possess a much higher therapeutic potential, due to their unique properties, and they are derived from a four or five-day-old human embryo. ES are able to produce all of the body’s cells, propagate quickly and serve as a source of replacement cells and tissue for damaged organs.

Properties of human stem cells have led to extensive R&D investments- and raised the necessity of protecting these assets through adequate IP legal instruments.

Ethical Issues Related to Human ES Cells

The attention toward stem cells has been growing in Mexico in the last few years. The Mexican Society for Stem Cell Research was founded in 2014 and the National Council of Science and Technology has several grant programs for research within the field of adult stem cells.In Mexico, claims related to adult stem cells have been rejected by the Mexican Institute of Industrial Property (IMPI) until not so long ago. However, such institute, in a truly surprising and radical change on the subject, has recently indicated that adult stem cells can be considered perfectly patentable.For embryonic stem cells, however, it’s another matter.

Article 4 of the Mexican Industrial Property Law, states that

“No patent, registration or authorisation shall be granted, nor shall any publicity be given in the Gazette in respect of any of the legal devices or institutions regulated by this law, where their contents or form are contrary to public policy doctrine, morals or good practices, or if they violate any legal provision.”

The Mexican Institute of Industrial Property (IMPI) referred to this article to deny the patentability of ES cells. Indeed, the procedure for extracting ES cells require the destruction of the human embryo: an act that IMPI considered as contrary to public morality – as a consequence, the IMPI has rejected patent applications concerning ES cells.

Mexico is not unique in rejecting inventions relating to human ES cells.

In 2009, the European Patent Office Opposition Division ruled against the “Edinburgh Patent” (T1079/03), arguing that wherein human embryos would be destroyed in the process to obtain ES stem cells, the invention was to be considered against Article 53(a) and Rule 23d(c) of the European Patent Convention (EPC) and therefore not patentable.In 2010, the European Patent Office’s enlarged Board of Appeal similarly denied the patentability of biotechnological inventions which require the destruction of the human embryos for industrial or commercial purposes.

On the other hand, the EPO in practice admits these type of patents if the applicant demonstrates that the Stem cells could have been obtained without destroying the human embryo.

New Requirements to Stem Cells Patentability

This is exactly the route that Mexico may be following in the future. Since 2008, evolvements in biotechnological techniques have made possible to obtain human ES cells without the destruction of a human embryo.

These new methods of obtaining human ES cells could effectively circumvent the morality provisions. While filing a patent application, then, the applicant must clearly specify that the ES cells can be obtained without destruction of the human embryo and that this alternative method was already known and available to the public at the time of filing. In other words, the applicant has to prove that the invention could be performed without necessitating the destruction of an embryo at the filing date of the patent application.

 




The materials available at this blog are for informational purposes only and not for the purpose of providing legal advice. You should contact your attorney or Moeller IP directly to obtain advice with respect to any particular issue or problem. Use of and access to this blog or any of the links contained within the blog do not create an attorney-client relationship between Moeller IP and the user or browser. The opinions expressed at or through this site are the opinions of the individual author and may not reflect the opinions of the firm or any individual attorney.
Moeller IP Advisors

Moeller IP